Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO212 in Astrocytoma, Glioblastoma, or Brain Metastases
NCT06047379Phase 2Recruiting
- Sponsor
- NeOnc Technologies Holdings, Inc.
- Start
- Nov 2023
- Primary completion
- Feb 2027
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label trial of NEO-212 in astrocytoma, glioblastoma (GBM) and brain metastases (8 arms), sponsored by NeOnc Technologies Holdings, Inc. Primary endpoints: Safety and tolerability of increasing dose levels of orally administered NEO212 at 6 months, Maximum Tolerated Dose at 6 months and 3 more. Started Nov 2023; status: recruiting.
02
Drugs
NEO-212
03
Conditions
astrocytomaglioblastoma (GBM)brain metastases
Beyond the preview
Go deeper on NCT06047379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06047379.